Julia is chair and director of the institute of clinical pharmacology at the university hospital of RWTH Aachen since October 2019. As clinical pharmacologist she worked for seven years in drug regulation and research as vice president of the German drug regulatory authority, BfArM. Her research mostly focuses on Personalized Medicine and patient risk profiles for adverse drug events and therapeutic failure. She pioneered the systematic development of personalized dose adjustments promoting the way of pharmacogenetics from bench to bedside. She is involved in many European projects, and has been the coordinator of a European project on Strengthening training of academia in regulatory sciences (STARS) until her move to university. J Stingl has authored more than 250 publications in peer-reviewed scientific journals, has been cited more than 10,000 times with an average citation of 30 per article and an H-index of 53 (ISI web of science, Aug 2021).
Julia was recipient of the Utrecht Award for Pharmaceutical Research in 2009 and awarded with the Leon I. Goldberg Young Investigator Award of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) in 2010.
Since 2012, Julia is member of the Pharmacogenomics Working Party (PGWP) and serves as expert for the European Medicines Agency (EMA). Since 2019, she is member of the gene diagnostic committee in Germany. Since 2004 she is extraordinary member of the Drug Commission of the German Medical Association (AKDAE).